English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NA /

AV-951-20-304

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study To Compare Tivozanib In Combination With Nivolumab To Tivozanib In Subjects With Renal Cell Carcinoma Who Have Progressed Following One Or Two Lines Of Therapy, One Of Which Is An Immune Checkpoint Inhibitor

DISEASE GROUP:
Genito-Urinary
current phase:
Phase III
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: